19 Jan 2026 | 5 Mins Read
Syngene extends BMS research partnership to 2035
Flipitmoney
Syngene International has extended its 25-year partnership with Bristol Myers Squibb until 2035. The expanded pact broadens services across the drug development lifecycle, enabling seamless transition from early research to commercialization and positioning Syngene to support BMS’s next wave of global discovery, development, and manufacturing programmes.